Please assess the completion status of the following clinical trial:

Trial Title: Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female ≥ 18 to ≤ 80 years of age~* Subject not at LDL-C goal~* History of statin intolerance~* Lipid lowering therapy has been stable prior to enrolment for at least 4 weeks~* Fasting triglycerides ≤ 400 mg/dL~Exclusion Criteria:~* New York Heart Association (NYHA) III or IV heart failure~* Uncontrolled cardiac arrhythmia~* Uncontrolled hypertension~* Type 1 diabetes~* Poorly controlled type 2 diabetes~* Uncontrolled hypothyroidism or hyperthyroidism

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Part A: Atorvastatin 20 mg => Placebo (Type: OTHER): Participants received atorvastatin 20 mg orally for 10 weeks (period 1) followed by placebo orally for 10 weeks (period 2), separated by a 2-week washout period.
- Part A: Placebo => Atorvastatin 20 mg (Type: OTHER): Participants received placebo orally for 10 weeks (period 1) followed by atorvastatin 20 mg orally for 10 weeks (period 2), separated by a 2-week washout period.
- Part B: Ezetimibe (Type: ACTIVE_COMPARATOR): Participants received 10 mg ezetimibe orally only a day and placebo to evolocumab by subcutaneous injection once a month for 24 weeks.
- Part B: Evolocumab (Type: EXPERIMENTAL): Participants received 420 mg evolocumab by subcutaneous injection once a month and placebo to ezetimibe orally once a day for 24 weeks.
- Part C: Open-label Evolocumab (Type: EXPERIMENTAL): Participants who completed part B and were eligible to proceed to open-label extension part C and could choose quarterly between evolocumab 420 mg once a month or evolocumab 140 mg every 2 weeks for up to 2 years.

Based on this trial design, predict the completion outcome and termination type (if applicable).